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Abstract
Infectious antigens may be triggers for the exacerbation of
systemic lupus erythematosus. The underlying mechanism
causing acceleration and exacerbation of lupus nephritis (LN) is
largely unknown. Bacterial lipopolysaccharide (LPS) is capable
of inducing an accelerated model of LN in NZB/W mice,
featuring diffuse proliferation of glomerular resident cells. We
hypothesized that mesangial cells (MCs) from LN subjects are
more responsive to LPS than normal subjects. Cultured primary
NZB/W and DBA/W (nonautoimmune disease-prone strain with
MHC class II molecules identical to those of NZB/W) MCs were
used. Monocyte chemoattractant protein-1 (MCP-1) and
osteopontin (OPN) expressions either in the baseline (normal
culture) condition or in the presence of LPS were evaluated by
real-time PCR, ELISA, or western blot analysis. NF-κB was
detected by ELISA, electrophoresis mobility-shift assay, and
immunofluorescence. First, either in the baseline condition or in
the presence of LPS, NZB/W MCs produced significantly
higher levels of MCP-1 and OPN than the DBA/W MC controls.
Second, NZB/W MCs expressed significantly higher levels of
Toll-like receptor 4, myeloid differentiation factor 88, and NF-κB
than the DBA/W MC controls, both receiving exactly the same
LPS treatment. In conclusion, NZB/W MCs are significantly
more sensitive than their normal control DBA/W MCs in
producing both MCP-1 and OPN. With LPS treatment, the
significantly elevated levels of both chemokines produced by
NZB/W MCs are more likely due to a significantly greater
activation of the Toll-like receptor 4-myeloid differentiation factor
88-associated NF-κB pathway. The observed abnormal
molecular events provide an intrarenal pathogenic pathway
involved in an accelerated type of LN, which is potentially
infection triggered.
Introduction
Lupus nephritis (LN) is a major complication of systemic lupus
erythematosus and is associated with high rates of morbidity
and mortality. Although clinical signs of renal involvement
appear in only 50–80% of patients, the disease involves the
kidney in almost all patients from whom sufficient tissue can be
obtained for analysis [1]. Both renal and extrarenal events are
involved in the pathogenesis of the disease. Bacterial and viral
infections may serve as environmental triggers for the develop-
ment or exacerbation of systemic lupus erythematosus in
genetically predisposed individuals. Lupus patients are more
prone to develop common (pneumonia, urinary tract infection,
cellulitis, and sepsis), chronic (tuberculosis), and opportunistic
infections, possibly because of genetic and immunologic
defects [2]. Experimentally, when exposed to bacterial lipopol-
ysaccharide (LPS), NZB/W mice promptly developed an
accelerated diffuse proliferative nephritis [3,4], clinically and
pathologically mimicking the transformation of renal lesion
DBA/W = DBA-2  NZW; ELISA = enzyme-linked immunosorbent assay; FBS = fetal bovine serum; IL = interleukin; LN = lupus nephritis; LPS = 
lipopolysaccharide; MC = mesangial cell; MCP-1 = monocyte chemoattractant protein-1; MHC = major histocompatibility complex; MyD88 = myeloid 
differentiation factor 88; NF = nuclear factor; NZB/W = NZB  NZW; OPN = osteopontin; PCR = polymerase chain reaction; TLR-4 = Toll-like recep-
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types from low grade to high grade in LN patients. Although
increased immune complex deposition and proliferation of
intrinsic cells in the affected glomeruli were observed in the
NZB/W mice that received LPS administration [3], the actual
mechanisms underlying the accelerated form of the LN model
remain largely unclear. Recent studies suggest that mesangial
cells (MCs) play a critical role in LN and regulate inflammatory
responses inside the compromised glomeruli [5-9]. It is
unknown whether MCs of the lupus-prone mice are more sen-
sitive to an infectious agent than MCs of their normal control.
This prompted us to evaluate chemokine production by NZB/
W MCs both in the baseline (normal culture, 20% fetal bovine
serum (FBS)) condition and when exposed to bacterial LPS to
simulate (under 2% FBS), respectively, the normal physiologi-
cal status and superimposed infection.
Recent studies have demonstrated that expression of LPS-
induced monocyte chemoattractant protein-1 (MCP-1) [5] and
of the osteopontin (OPN) [9] gene is NF-κB dependent. MCP-
1, a CC chemokine, is mainly released by activated monocyte/
macrophages, T cells, and natural killer cells, and attracts leu-
kocytes and other mediators to sites of inflammation [6-8].
Cultured renal parenchymal cells, including MCs and renal
tubular epithelial cells, produce MCP-1 in response to proin-
flammatory cytokines [10,11]. OPN is a chemotactic factor for
monocytes and is an important mediator in glomerulonephritis
[12-14]. OPN mRNA and protein are detected in cultured
MCs subjected to a variety of stimuli [15,16]. Both of these
chemokines play a crucial role in the pathogenesis of LN [17-
19]. Toll-like receptor 4 (TLR-4) has been implicated in LPS
signaling and is involved in the renal disease induced by
expose to bacterial components [20-22]. TLR-4 mediates LPS
signal transduction in collaboration with other molecules, such
as CD14 and myeloid differentiation factor 88 (MyD88),
resulting in rapid NF-κB activation [20,23].
In the present study, we demonstrated that NZB/W MCs
(lupus-prone strain) produce significantly more chemokines
than DBA/W MCs [24] (as the normal control; DBA/W mice
are a nonautoimmune disease-prone strain with MHC class II
molecules identical to those of NZB/W mice), both in the
baseline (normal culture) condition and in response to LPS
stimulation. This might explain how an infectious antigen trig-
gers an accelerated and aggravated glomerular proliferative
lesion in terms of intrinsic factors in the kidney.
Materials and methods
Primary culture of mesangial cells
Both female NZB/W and DBA/W F1 mice were obtained from
the Animal Center of the College of Medicine of National Tai-
wan University and were maintained by the Animal Center of
our National Defense Medical Center in a specific pathogen-
free facility. All animal experiments were performed with the
approval of the Institutional Animal Care and Use Committee
of The National Defense Medical Center, Taiwan, and were
consistent with the NIH Guide for the Care and Use of Labo-
ratory Animals.
DBA/W F1 mice are a nonautoimmune disease-prone strain
with MHC class II molecules identical to those of NZB/W
mice. DBA/W mice do not spontaneously develop autoim-
mune disease; mice were monitored throughout their lifespan
and show no proteinuria or detectable anti-double-stranded
DNA or anti-DNA antibodies [24]. Aware that glomerulone-
phritis spontaneously develops in NZB/W mice beginning at
22–26 weeks of age, we chose to isolate glomeruli of female
mice 7–8 weeks old for the following primary MC culture. Age-
matched female DBA/W mice were used as the controls. The
preparation of primary cultures of MCs was performed as
described previously [25,26] with mild modification. Briefly,
glomeruli were purified from minced renal cortex by serial siev-
ing through meshes of different pore sizes, then the glomeruli
suspension was digested for 20 minutes at 37°C with type IV
collagenase, and the dissociated glomerular cells were cul-
tured in RPMI 1640 medium containing 20% heat-inactivated
endotoxin-free FBS, penicillin/streptomycin, and HEPES (10
mM) (GIBCO, Invitrogen, Carlsbad, CA, USA). The MCs show
typical morphologic characteristics – positive for both α-
smooth muscle actin and vimentin stain, but E-cadherin-nega-
tive as described previously [26]. The cultured MCs were
used for experiments between passages 6 and 10.
Experimental protocol
The cultured MCs were either plated in 20% FBS medium
(baseline or normal culture condition) or arrested in 2% FBS
medium for 2 hours, and were then incubated without or with
10  μg/ml LPS (Salmonella minnesota Re595; Sigma, St
Louis, MO, USA) for mRNA analyses, protein analyses, and
NF-κB activation assays at various time points. In the inhibition
studies, cultured MCs were pretreated for 2 hours with a NF-
κB inhibitor, n-tosyl-1-phenylalanine chloromethyl ketone or
dexamethasone (both from Sigma), before addition of LPS to
the cultures. The doses of pharmacological agents used were
not cytotoxic for the cells as shown by the lactate dehydroge-
nase test.
Proliferation assay
MCs were plated in 96-well plates. The cells were subse-
quently arrested in 2% FBS medium for 2 hours, and were
then incubated without or with 10 μg/ml LPS for 6, 12, 24, or
48 hours. Methyl thiazoleterazolium (5 mg/ml; Sigma) was
added (20 μl/well) and the mixture was incubated for 3 hours
at 37°C. Dimethy-sulforide (Merck, Darmstadt, Germany) was
then added (150 μl/well) for 15 minutes. The absorbance at
540 nm was determined using an ELISA plate reader (Bio-Tek,
Burlington, VT, USA). The arithmetic mean optical density of
six wells for each experimental point was used for cell prolifer-
ation levels.Available online http://arthritis-research.com/content/9/4/R67
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Real-time PCR
The total RNA was isolated from the MCs using TriZOL rea-
gent according to the manufacturer's instructions (Invitrogen).
For first-strand cDNA synthesis, 1.5 μg total RNA was used in
a single-round reverse transcriptase reaction (total volume 25
μl), containing 0.9 μl Oligo(dT)12–18 primer, 1.0 mM dNTPs, 1
× first-strand buffer, 0.4 mM dithiothreitol, 80 U RNase out-
recombinant ribonuclease inhibitor, and 300 U Superscript II
RNase H (Invitrogen). Real-time PCR was subsequently per-
formed in the ABI Prism 7700 Sequence Detection System
(Perkin Elmer Applied Systems, Foster City, CA, USA) using
the SYBR Green I PCR kit (Perkin Elmer Applied Systems).
Each reaction contained 25 μl of 2 × SYBR green Master Mix,
300 nM primers, 5 μl of 1:10 dilution of the cDNA prepared
above, and water to 50 μl. The reactions were then followed
by 40 cycles of 30 seconds at 94°C, of 30 seconds at 60°C,
and of 60 seconds at 72°C.
The primers used in this study were as follows: mouse β-actin,
forward 5'-GACGGCCAGGTCACTAT-3' and reverse 5'-
ACATCTGCTGGAAGGTGGAC-3'; mouse MCP-1, forward
5'-AGGTCCCTGTCATGCTTCTGG-3' and reverse 5'-
ACAGTCCGAGTCACACTAGTTCA-3'; mouse OPN, for-
ward 5'-CTCGTGCAGGAAGAACAGAAGC-3' and reverse
5'-GAGTCAAGTCAGCTGGATGAACC-3'; mouse TLR-4,
forward 5'-CTCACAGATAGCCTGGCCAATC-3' and reverse
5'-CCATCTCACAAGGCATGTCCAG-3'; and mouse
MyD88, forward 5'-ACTCCTTCATGTTCTCCATACC-3' and
reverse 5'-ATCGAAAAGTTCCGGCGTTTGT-3'. The house-
keeping gene β-actin was used as the internal standard.
Immunocytochemistry and immunofluorescence
MCs were grown on glass slides and were fixed with 2% para-
formaldehyde for 15 minutes. For immunocytochemistry, to
study α-smooth muscle actin, vimentin, and E-cadherin, the
sections were incubated overnight at 4°C with biotin-labeled
mouse anti-α-smooth muscle actin (Neomarkers, Fremont,
CA, USA), with goat antivimentin or anti-E-cadherin antibodies
(Santa Cruz Inc., Santa Cruz, CA, USA), and then for 1 hour at
room temperature with a streptavidin peroxidase system
(DAKO, Carpinteria, CA, USA) or horseradish peroxidase-con-
jugated rabbit anti-goat antibody. Sections were counter-
stained with hematoxylin.
For immunofluorescence, to study NF-κB p65, the sections
were incubated overnight at 4°C with rabbit anti-NF-κB p65
antibody (Abcam, Cambridge, MA, USA), and then for 2 hours
at room temperature with fluorescein isothiocyanate-conju-
gated goat anti-rabbit IgG antibody (Cappel; Organon
Teknika, Durham, NC, USA). The percentage of MCs showing
nuclear NF-κB p65 was determined by counting at least 500
cells in each well under high power (×400) [13].
Nuclear protein extraction
Nuclear extracts were prepared using a nuclear extract kit
(Active Motif, Carlsbad, CA, USA) according to the manufac-
turer's instructions. The protein was measured using a Pierce
BCA protein assay kit (Perbio Science, Etten-Leur, The
Netherlands).
Enzyme-linked immunosorbent assay
MCP-1 protein in culture supernatants was measured using
commercial ELISA kits (Biosciences, Los Angeles, CA, USA)
according to the manufacturer's instructions. The absorbance
at 450 nm was determined using an ELISA plate reader (Bio-
Tek). The MCP-1 protein expression levels at various time
points were normalized to total protein as picograms per
milligram.
Activation of the transcription factors, NF-κB p65 and activa-
tor protein-1, was measured in MC nuclear extracts using
Trans-AM ELISA assay kits (Active Motif Europe, Rixensart,
Belgium) according to the manufacturer's instructions. The
absorbance was determined at 450 nm using an ELISA plate
reader (Bio-Tek). Mouse recombinant NF-κB p65 (Active Motif
Europe) was used as the standard to determine the concen-
tration of NF-κB p65, and then the levels were normalized to
nuclear protein as nanograms per milligram.
Electrophoresis mobility-shift assay
For NF-κB activation, a nonradioactive electrophoresis mobil-
ity-shift assay kit was used according to the manufacturer's
instructions (Panomics, Fremont, CA, USA). Six micrograms of
nuclear protein were incubated for 30 minutes at room tem-
perature with a biotinylated oligonucleotide containing the NF-
κB-binding site, and then the samples were separated on a
nondenaturing polyacrylamide gel (6%, with 2.5% glycerol)
and blotted onto a Biodyne B (0.45 μm) positively charged
nylon membrane (Pall Schweiz AG, Basel, Switzerland). The
biotinylated nucleotides were detected using alkaline phos-
phatase-conjugated streptavidin and Chemiluminescent Rea-
gent Plus (PerkinElmer Life Sciences, Boston, MA, USA) on
film as described previously [27].
Western blot analysis
For detection of cytoplasmic OPN, MCs were harvested and
incubated for 20 minutes on ice in lysis buffer (20 mM Tris, pH
7.4, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM eth-
ylenediamine tetraacetic acid, and a protease inhibitor), and
were then centrifuged at 14,000 rpm for 20 minutes. The pro-
tein concentration was determined with a BCA protein assay
reagent (Perbio Science). The proteins were separated on a
10% SDS-PAGE gel and transferred to a polyvinylidene diflu-
oride membrane (Millipore, Bedford, MA, USA), which was
then incubated for 2 hours in 20 ml of 5% skim milk in Tris-buff-
ered saline (0.05 M Tris-HCl, 0.9% NaCl, pH 7.4). The mem-
brane was incubated overnight at 4°C with rabbit anti-OPN
antibodies (Assay Designs, Ann Arbor, MI, USA) in Tris-buff-Arthritis Research & Therapy    Vol 9 No 4    Ka et al.
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ered saline, and then, after three washes, for 1 hour at room
temperature with horseradish peroxidase-conjugated goat
anti-rabbit antibodies (Pierce, Rockford, IL, USA) in Tris-buff-
ered saline. Bound antibody was detected using Chemilumi-
nescent Reagent Plus (PerkinElmer Life Sciences) on film.
Statistical analysis
All results are expressed as the mean ± standard error. Com-
parisons between two groups were made by an unpaired Stu-
dent's  t  test. Differences among multiple groups were
determined with one-way analysis of variance using Tukey's
method for post-hoc analysis. P < 0.05 was considered statis-
tically significant.
Results
mRNA expression of MCP-1 and osteopontin in the 
baseline (normal culture) condition
Under the baseline (normal culture, 20% FBS) condition, to
determine whether the NZB/W MCs are 'hyperreactive' to
chemokine production, the cells were plated in 20% FBS for
0–12 hours, and the levels of the chemokine transcripts were
measured at the various time points. DBA/W mice are a non-
autoimmune disease-prone strain with MHC class II molecules
identical to those of NZB/W mice [24]. We used DBA/W
MCs as the normal control throughout the experiment.
The levels of MCP-1 mRNA (P < 0.01) (Figure 1a) and of OPN
mRNA (P < 0.05) (Figure 1b) at 6 and 12 hours were signifi-
cantly higher in NZB/W MCs than in the DBA/W MC controls
– although there was no significantly enhanced protein level of
each of the chemokines of the NZB/W MCs, compared with
the DBA/W MC controls. The latter effect could be due to the
interference by serum (20% FBS) per se in the culture medium
for protein extracted from the cultured cells or their
supernatant.
The data suggest that NZB/W MCs are obviously hyperreac-
tive in producing the two chemokines under the baseline (nor-
mal culture) condition.
mRNA and protein expressions of MCP-1 and 
osteopontin under LPS stimulation
Cavallo and Granholm [3] demonstrated that the LPS-induced
accelerated LN model in mice features significant proliferation
of glomerular intrinsic cells, including MCs; however, the bio-
logical mode of action of the latter involved in the pathogene-
sis of the LPS-induced accelerated LN model remains largely
unknown. To determine whether NZB/W MCs are capable of
producing more MCP-1 and OPN than the DBA/W MC con-
trols, when exposed to LPS (S. minnesota, the same source of
LPS that was used to induce the accelerated LN model [3])
the cells were arrested in 2% FBS medium for 2 hours, and
were then incubated with LPS (10 μg/ml) for 0–12 hours.
Our preliminary data showed that the concentration of LPS
was not cytotoxic throughout the experiment. First, the real-
time PCR showed an increase in MCP-1 mRNA levels after 6
or 12 hours (Figure 2a) and in OPN mRNA levels at 6 or 12
hours (Figure 2b) of LPS treatment in NZB/W MCs, and these
increases were significantly higher than those in the identically
treated DBA/W MC control (P < 0.05). Second, the ELISA
showed significantly higher MCP-1 levels in the medium of
NZB/W MC cultures compared with DBA/W MC cultures
after 12 or 24 hours of incubation with LPS (P < 0.01) (Figure
2c). Western blot analysis also showed greatly enhanced lev-
els of OPN in NZB/W MCs compared with the DBA/W MC
controls at the same times (both, P < 0.005) (Figure 2d).
These data indicate that MCs from NZB/W mice (lupus-prone
strain) are more sensitive than the DBA/W MC controls to LPS
stimulation.
Figure 1
Monocyte chemoattractant protein-1 and osteopontin mRNA expression in NZB/W mesangial cells under the baseline condition Monocyte chemoattractant protein-1 and osteopontin mRNA expression in NZB/W mesangial cells under the baseline condition. Mesangial cells 
were incubated in the baseline (normal culture, 20% fetal bovine serum (FBS)) condition for different periods of time, and then levels of (a) mono-
cyte chemoattractant protein-1 (MCP-1) mRNA or (b) osteopontin (OPN) mRNA were examined by real-time PCR. The experiment was performed in 
triplicate, and results are expressed as the mean ± standard error, n = 6. *P < 0.05, **P < 0.01.Available online http://arthritis-research.com/content/9/4/R67
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Involvement of the TLR-4-MyD88 pathway in mesangial 
cells treated with LPS
The TLR-4 pathway has recently been shown to act as a signal
transducer for LPS in various tissues, resulting in cellular acti-
vation and the release of cytokines, chemokines, reactive oxy-
gen species, and nitric oxide [20,28,29]. As shown in Figure
3, up-regulation of both the TLR-4 and MyD88 transcripts was
observed in the NZB/W MCs after 1, 3, or 6 hours of LPS
stimulation, compared with the DBA/W MC controls that were
identically treated (each, P < 0.05).
Involvement of NF-κB activation in mesangial cells 
treated with LPS
Phosphorylation of NF-κB p65 is required for optimal induc-
tion of the NF-κB target genes in response to a variety of
proinflammatory stimuli, including MCP-1 [5] and OPN [9].
We evaluated whether the NF-κB p65 activation occurred in
NZB/W MCs under LPS stimulation, and compared it with that
in the DBA/W MC controls using immunofluorescence, the
electrophoresis mobility-shift assay, and the ELISA.
First, as shown in Figure 4a, the NF-κB p65 was markedly
present in the nuclei of the NZB/W MCs after 3 and 6 hours
(Figure 4, images a-c and i; P < 0.005), respectively, of LPS
stimulation, and then fell to basal levels at 12 hours (Figure 4a,
images d and i). In contrast, the DBA/W MC controls (Figure
4a, images f-h and i) showed only little NF-κB p65 in their
nuclei after incubation with LPS.
Second, the electrophoresis mobility-shift assay further con-
firmed the activation of NF-κB p65 by showing significantly
stronger NF-κB DNA binding in NZB/W MCs than in DBA/W
MC controls, after 3 and 6 hours of LPS stimulation (Figure
4b). Using the ELISA, again NZB/W MCs showed significantly
higher levels of nuclear NF-κB p65 than those of the DBA/W
MC controls (1.68 ± 0.04 or 2.26 ± 0.22 ng/mg nuclear pro-
tein compared with 1.16 ± 0.07 or 0.88 ± 0.17 ng/mg nuclear
Figure 2
Monocyte chemoattractant protein-1 and osteopontin expression in NZB/W mesangial cells with lipopolysaccharide treatment Monocyte chemoattractant protein-1 and osteopontin expression in NZB/W mesangial cells with lipopolysaccharide treatment. Growth-arrested 
(under 2% fetal bovine serum (FBS)) mesangial cells were incubated with 10 μg/ml lipopolysaccharide (LPS) for different periods of time, and then 
levels of (a) monocyte chemoattractant protein-1 (MCP-1) mRNA or (b) osteopontin (OPN) mRNA were examined by real-time PCR. (c) MCP-1 pro-
tein levels in the culture supernatant were measured by ELISA. (d) OPN protein levels in the cell lysate were measured by western blot analysis; 
semiquantitative data are shown. The MCP-1 protein expression levels at various time points were normalized to total protein (pg/mg). The experi-
ment was performed in triplicate, and results are expressed as the mean ± standard error, n = 6. The last time point without LPS stimulation (unstim-
ulated) was presented as the negative control. *P < 0.05, **P < 0.01, ***P < 0.005.Arthritis Research & Therapy    Vol 9 No 4    Ka et al.
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protein after 3 or 6 hours, respectively; P < 0.005) under LPS
treatment (Figure 4c).
Third, a transcription factor – activator protein-1, sometimes
together with NF-κB – is involved in a variety of signaling path-
ways [9]. The ELISA confirmed that only low levels of activator
protein-1, however, were detectable in both of the MCs, and
there was no significant difference between them (data not
shown).
Finally, NZB/W MCs were preincubated for 2 hours with n-
tosyl-1-phenylalanine chloromethyl ketone (2.5–10 μM) or
with dexamethasone (1–20 μM) (both as NF-κB inhibitors),
and were then subjected to the same LPS treatment (12 hours
for mRNA analysis and 24 hours for protein analysis, respec-
tively) as that mentioned above. All concentrations of n-tosyl-
1-phenylalanine chloromethyl ketone and the highest concen-
tration of dexamethasone inhibited the LPS-induced increase
in MCP-1 mRNA (Figure 5a) and in OPN mRNA (Figure 5b)
levels in NZB/W MCs and the LPS-induced increase in pro-
tein levels of MCP-1 (ELISA; Figure 5c) and of OPN (western
blot analysis; Figure 5d).
In summary, the data show that, under LPS stimulation, NZB/
W MCs exhibited a significantly augmented activation of the
TLR-4-MyD88-NF-κB signaling pathway, and its resultant sig-
nificantly enhanced production of MCP-1 and of OPN, com-
pared with the DBA/W MC controls.
Discussion
Cavallo and Granholm [3,4] established a LPS-induced accel-
erated LN model in NZB/W mice. In the present study, we
detected chemokine productions by NZB/W MCs both in the
baseline (normal culture, under 20% FBS) condition and when
exposed to bacterial LPS (under 2% FBS), respectively, and
we performed mechanistic experiments to dissect the poten-
tial mechanisms responsible for the events.
Glomerular infiltration of monocytes/macrophages is fre-
quently observed in a variety of human LN [30,31] and the
chemokine most commonly involved in renal monocytes/mac-
rophages recruitment is MCP-1 [19,32]. OPN is a chemoat-
tractant and has also been shown to recruit monocytes into
the interstitium of the kidney in LN [17,33]. Both the chemok-
ines have been identified as highly expressed in MCs under
disease conditions [10,34].
In the present study, we first demonstrated that NZB/W MCs
are hyperreactive to generate MCP-1 and OPN in the baseline
(normal culture, 20% FBS) condition. We also observed that
NZB/W MCs expressed much higher levels of IL-6 and induc-
ible nitric oxide synthase mRNAs than the DBA/W MC con-
trols in the baseline (normal culture, 20% FBS) condition,
although there was no significant difference in mRNA levels of
IL-1β, IL-4, IL-12 or TNFα between NZB/W MCs and DBA/W
MCs (unpublished data). We believe that NZB/W MCs of the
lupus-prone mice are very likely to be 'hypersensitive' in their
physiological growth status. The mechanisms responsible for
the NZB/W MCs being obviously hyperreactive in producing
the two chemokines (OPN and MCP-1) under the baseline
condition need further investigation, although we thought that
the complicated genetic defect of lupus-prone mice could be
one of the potential mechanisms responsible for this particular
property. On the other hand, it has been observed that MCP-
1 mRNA levels are increased in LPS-induced renal tubular cell
injury [5] and in urinary sediment of lupus patients [30], reflect-
ing LN activity. OPN, which similarly acts both as a chemokine
and as a cytokine, is detected in the glomerular crescents of
severe forms of experimental glomerulonephritis [12,13] and
in human LN [14]. Similarly, we found that NZB/W MCs are
Figure 3
Toll-like receptor 4 and myeloid differentiation factor 88 mRNA in NZB/W mesangial cells (lipopolysaccharide treatment) Toll-like receptor 4 and myeloid differentiation factor 88 mRNA in NZB/W mesangial cells (lipopolysaccharide treatment). Growth-arrested (under 
2% fetal bovine serum (FBS)) mesangial cells were incubated with 10 μg/ml lipopolysaccharide (LPS) for different periods of time, and then Toll-like 
receptor 4 (TLR-4) and myeloid differentiation factor 88 (MyD88) mRNA levels were measured by real-time PCR analysis. The experiment was per-
formed in triplicate, and results are expressed as the mean ± standard error, n = 6. The last time point without LPS stimulation (unstimulated) was 
presented as the negative control. *P < 0.05, **P < 0.01.Available online http://arthritis-research.com/content/9/4/R67
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also sensitive to producing significantly greater levels of chem-
okines (MCP-1 and OPN) in response to LPS stimulation
(under 2% FBS) than the DBA/W MC controls. These findings
support the observations that an environmental infectious
agent, LPS, may contribute to the exacerbation of LN [2,35].
We then examined and compared the role of TLR-4-MyD88-
NF-κB pathway potentially involved in the NZB/W MCs that
produced significantly more MCP-1 and OPN than the DBA/
W MC controls under LPS treatment. As expected, NZB/W
MCs showed a significantly enhanced activation of the TLR-4-
MyD88-NF-kB pathway, although the lack of protein data for
TLR-4 and MyD88 impaired interpretation of the results. In
some cell types [36] and tissues [37], the effects of bacterial
LPS on target cells were mediated through the TLR-4-MyD88-
dependent LPS signaling pathway. Several proteins other than
TLR-4 are also involved in LPS signaling. CD14 and MD-2 are
helper molecules for TLR4 and are required for LPS
recognition [20,23]. MyD88, an adapter molecule, is an essen-
tial component in the downstream signaling of Toll-like recep-
tors [20,38]. We observed that NZB/W MCs showed much
greater LPS-induced increases in TLR-4 mRNA and in MyD88
mRNA than the DBA/W MC controls. Activation of the TLR-4-
MyD88-dependent pathway by LPS leads to the activation of
NF-κB [23], an inducible transcription factor involved in
cytokine-mediated inflammation [ 3 9 ]  a n d  i n  L N  [ 4 0 ] .  W e
detected a rapid and much greater increase in NF-κB p65
activation in NZB/W MCs after LPS stimulation compared
with that in the DBA/W MC controls (Figure 4). The NF-κB
inhibitors (n-tosyl-1-phenylalanine chloromethyl ketone and
dexamethasone) markedly reduced LPS-induced MCP-1 and
OPN production (Figures 5), suggesting a major role for NF-
κB in NZB/W MCs that are more responsive to LPS. On the
other hand, MCs also express Toll-like receptor-2 [41] and
Toll-like receptor-3 [21] that caused secretion of proinflamma-
tory cytokines. C5a receptor activation in MCs was capable of
inducing proliferation, a selective production of cytokines and
growth factors [42]. In the present study, we could not exclude
Figure 4
NF-κB p65 activation in NZB/W mesangial cells with lipopolysaccharide treatment NF-κB p65 activation in NZB/W mesangial cells with lipopolysaccharide treatment. Growth-arrested (under 2% fetal bovine serum (FBS)) mesang-
ial cells (MCs) were incubated with 10 μg/ml lipopolysaccharide (LPS) for different periods of time, and then the distribution of NF-κB p65 was 
examined. (a) Immunofluorescence: images a–d, NZB/W MCs; images e–h, DBA/W MCs (nonimmune strain, served as control) incubated for 0–12 
hours with LPS; and image i, semiquantitative data. (b) Electrophoresis mobility-shift assay performed using a DIG-labeled synthetic oligonucleotide 
and nuclear extract from MCs. The competition assay used the same unlabeled oligonucleotide at a 10-fold higher concentration. Arrow, NF-κB p65 
binding bands. Comp., the abbreviation of competition. (c) ELISA performed using the TransAM NF-κB p65 kit. The NF-κB p65 expression levels at 
various time points were normalized to nuclear protein (ng/mg). The experiment was performed in triplicate, and results are expressed as the mean ± 
standard error, n = 6. The last time point without LPS stimulation (unstimulated) was presented as the negative control. ***P < 0.005 versus DBA/W 
MC controls.Arthritis Research & Therapy    Vol 9 No 4    Ka et al.
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the involvement of other signaling pathways in the activation of
MCs.
The genetic basis of NZB/W mice is a complex one. In this
regard, NZB/NZW mice have been extensively analyzed with
respect to the genomic locations of susceptibility loci for
autoantibodies, glomerulonephritis, and other component
lupus phenotypes [43]. Importantly, Kikuchi and colleagues
[44] reported that the NZB autoimmunity 2 (Nba2) locus from
NZB mice is associated with autoantibody production and the
subsequent development of LN. Collectively, our data support
that the difference observed could be mainly encoded by the
NZB genome.
Based on our data, we believe that the observed high respon-
siveness towards production of chemokines, such as MCP-1
and OPN, by MCs from the lupus-prone NZB/W mice (NZB/
W MCs), both in the baseline (normal culture) condition and
upon LPS stimulation (mimicking the LPS-induced acceler-
ated LN model), could promote the development of the LPS-
induced accelerated LN model.
Conclusion
Our data might have clinical and pathological implications
helpful in the understanding of the potential mechanism for
transformation of renal lesion types from low grade to high
grade in some LN patients, and helpful in the medical
approach to systemic lupus erythematosus patients, associ-
ated with an incidental infection.
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Figure 5
NF-κB inhibitor effect on lipopolysaccharide-induced monocyte chemoattractant protein-1 and osteopontin expression in NZB/W mesangial cells NF-κB inhibitor effect on lipopolysaccharide-induced monocyte chemoattractant protein-1 and osteopontin expression in NZB/W mesangial cells. 
Growth-arrested (under 2% fetal bovine serum (FBS)) mesangial cells were preincubated for 2 hours with n-tosyl-1-phenylalanine chloromethyl 
ketone (TPCK) or dexamethasone (Dex), and then 10 μg/ml lipopolysaccharide (LPS) was added for 12 hours: (a) monocyte chemoattractant pro-
tein-1 (MCP-1) mRNA levels and (b) osteopontin (OPN) mRNA levels were measured by real-time PCR analysis. Growth-arrested (under 2% FBS) 
mesangial cells were preincubated for 2 hours with TPCK or Dex, then 10 μg/ml LPS was added for 24 hours: (c) MCP-1 protein levels in the super-
natant were measured by ELISA, and (d) OPN protein levels in the cell lysate were measured by western blot analysis; semiquantitative data are 
shown. The MCP-1 protein expression levels at various time points were normalized to total protein (pg/mg). The experiment was performed in tripli-
cate, and results are expressed as the mean ± standard error. **P < 0.01, ***P < 0.005, n = 6. White bar, absence of LPS; black bar, LPS alone; 
hatched bar, TPCK and LPS or Dex and LPS.Available online http://arthritis-research.com/content/9/4/R67
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